A new era for radiolabeled antibodies in cancer?

被引:61
作者
DeNardo, SJ [1 ]
Kroger, LA [1 ]
DeNardo, GL [1 ]
机构
[1] Univ Calif Davis, Med Ctr, Dept Hematol Oncol, Mol Canc Inst, Sacramento, CA 95816 USA
关键词
D O I
10.1016/S0952-7915(99)00017-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3-50-times higher than to the normal tissue with the next highest dose. RIT appears promising for future cancer therapy. Clinical responses in patients with advanced cancer have frequently been achieved with RIT as a single agent. Extended complete remissions and even increased survival have been achieved in lymphoma. Similar results in other cancers seem likely with RIT in combination therapy.
引用
收藏
页码:563 / 569
页数:7
相关论文
共 55 条
[1]  
Adams GP, 1998, IN VIVO, V12, P11
[2]   Pretargeting with the Affinity Enhancement System for radioimmunotherapy [J].
Barbet, J ;
Kraeber-Bodéré, F ;
Vuillez, JP ;
Gautherot, E ;
Rouvier, R ;
Chatal, JF .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1999, 14 (03) :153-166
[3]  
Behr TM, 1999, CANCER RES, V59, P2635
[4]  
Breitz HB, 1999, J NUCL MED, V40, p19P
[5]  
BREITZ HB, 1999, IN PRESS J NUCL MED
[6]  
Cagnoni P., 1998, CANCER BIOTHER RADIO, V13, P328
[7]   A revolution in the treatment of non-Hodgkin's lymphoma [J].
DeNardo, GL ;
O'Donnell, RT ;
Oldham, RK ;
DeNardo, SJ .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1998, 13 (04) :213-223
[8]  
DeNardo GL, 1997, CANCER, V80, P2706, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2706::AID-CNCR49>3.0.CO
[9]  
2-D
[10]   Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma [J].
DeNardo, GL ;
DeNardo, SJ ;
Goldstein, DS ;
Kroger, LA ;
Lamborn, KR ;
Levy, NB ;
McGahan, JP ;
Salako, Q ;
Shen, S ;
Lewis, JP .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3246-3256